Oligodendroglial tumors with marked desmoplasia: Clinicopathologic and molecular features of 7 cases

American Journal of Surgical Pathology

Volumn 35, Issue 6, 2011, Pages 845-852

  Jentoft, Mark ^a   Giannini, Caterina ^a   Rossi, Sabrina ^b   Mota, Renan ^a   Jenkins, Robert B ^a   Rodriguez, Fausto J ^a,c  

^a MAYO CLINIC   (United States)

^b Regional Hospital   (Italy)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1p19q; brain; desmoplasia; glioma; oligoastrocytoma; oligodendroglial tumors; oligodendroglioma

Indexed keywords

IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CANCER STAGING; CASE REPORT; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME ABERRATION; CHROMOSOME DELETION; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; OLIGODENDROGLIA; OLIGODENDROGLIOMA; PATHOLOGY;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OLIGODENDROGLIA; OLIGODENDROGLIOMA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL;

EID: 79958005779     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3182189693     Document Type: Article

References (17)

1. Armao DM, Stone J, Castillo M, et al. Diffuse leptomeningeal oligodendrogliomatosis: radiologic/pathologic correlation. AJNR Am J Neuroradiol. 2000;21:1122-1126. (Pubitemid 30390555)
2. Burger PC SB. Tumors of the Central Nervous System. Washington, DC: American Registry of Pathology; 2007.
3. Capper D, Reuss D, Schittenhelm J, et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 2011;121:241-252.
4. Di Rocco F, Carroll RS, Zhang J, et al. Platelet-derived growth factor and its receptor expression in human oligodendrogliomas. Neurosurgery. 1998;42:341-346. (Pubitemid 28076794)
5. Giannini C, Burger PC, Berkey BA, et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol. 2008;18:360-369. (Pubitemid 351782844)
6. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 2006;66:9852-9861. (Pubitemid 44672036)
7. Louis DN OH, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer; 2007.
8. McLendon RE, Rosenblum MK, Bigner DD, eds. Russell & Rubinstein's Pathology of Tumors of the Nervous System. London: Hodder Arnold; 2006.
9. Ramirez C, Bowman C, Maurage CA, et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors: towards individualized tumor treatment? Neuro Oncol. 2010;12:490-499.
10. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 1996;55:822-831. (Pubitemid 26238584)
11. Rodriguez FJ, Scheithauer BW, Jenkins R, et al. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol. 2007;31:351-362. (Pubitemid 46673108)
12. Rodriguez FJ, Scheithauer BW, Giannini C, et al. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 2008;113:2779-2789.
13. Rodriguez FJ, Mota RA, Scheithauer BW, et al. Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma. Brain Pathol. 2009;19:623-629.
14. Russell DS RL. Pathology of Tumours of the Nervous System. Baltimore: Williams & Wilkins; 1989.
15. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. 2000;18:636-645. (Pubitemid 30078545)
16. Smith JS, Wang XY, Qian J, et al. Amplification of the plateletderived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol. 2000;59:495-503. (Pubitemid 30368309)
17. Vyberg M, Ulhoi BP, Teglbjaerg PS. Neuronal features of oligodendrogliomasFan ultrastructural and immunohistochemical study. Histopathology. 2007;50:887-896. (Pubitemid 46850061)